<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/64300AF7-F2A5-4EEC-983A-CC4168C9C664"><gtr:id>64300AF7-F2A5-4EEC-983A-CC4168C9C664</gtr:id><gtr:name>Virginia Commonwealth University</gtr:name><gtr:address><gtr:line1>Virginia Commonwealth University</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Randall Div of Cell and Molecular Biophy</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/64300AF7-F2A5-4EEC-983A-CC4168C9C664"><gtr:id>64300AF7-F2A5-4EEC-983A-CC4168C9C664</gtr:id><gtr:name>Virginia Commonwealth University</gtr:name><gtr:address><gtr:line1>Virginia Commonwealth University</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1244339E-4070-4346-842C-EAB736E8A261"><gtr:id>1244339E-4070-4346-842C-EAB736E8A261</gtr:id><gtr:firstName>Tak</gtr:firstName><gtr:surname>Lee</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C68DCAD6-AB77-43CC-AEAF-45EB93348FA8"><gtr:id>C68DCAD6-AB77-43CC-AEAF-45EB93348FA8</gtr:id><gtr:firstName>Hannah</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Gould</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400106"><gtr:id>E3ABA361-9653-45F2-9013-E11EE555A8B7</gtr:id><gtr:title>Mechanisms of IgE Isotype Determination in Human B-cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400106</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>241005</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>IgE immunotherapy of cancer</gtr:description><gtr:id>2BBF3F2F-A35A-4634-A0D3-3D002AB38177</gtr:id><gtr:impact>one publication</gtr:impact><gtr:outcomeId>58E86D8B111-1</gtr:outcomeId><gtr:partnerContribution>Our collaborator hosted our PhD student for one year to carry out experiments.</gtr:partnerContribution><gtr:piContribution>We did the experiments</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Virginia Commonwealth University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CD23 effects on IgE synthesis</gtr:description><gtr:id>332C7066-2B2C-4FD6-8480-E19B219D31FD</gtr:id><gtr:impact>one publication</gtr:impact><gtr:outcomeId>31D49E13B50-1</gtr:outcomeId><gtr:partnerContribution>Provision of material and expertise</gtr:partnerContribution><gtr:piContribution>We did the experiments</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Intergenic transcription in Ig locus</gtr:description><gtr:id>C7ABD636-E7A7-476D-A9AF-66658BCABFD1</gtr:id><gtr:impact>two publications and continuing collabortion. A new BBSRC Project Grant to extend this study. Multidisciplinary between molecular and cell biology and immunology</gtr:impact><gtr:outcomeId>02A7B95C7C7-1</gtr:outcomeId><gtr:partnerContribution>Provision of expertise and a post-doctoral workers on the colalborative project</gtr:partnerContribution><gtr:piContribution>We did the experiments</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>458250</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>EC460992-16CA-43E4-9524-62D37983292E</gtr:id><gtr:outcomeId>tXHoa4Rac8B0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>E6412F54-A819-4FD4-B89B-53435BBD6BA7</gtr:id><gtr:outcomeId>UpaGbgw1sbE0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1840000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1100090</gtr:fundingRef><gtr:id>45E8406D-E112-4107-B5D7-204D7F29FC48</gtr:id><gtr:outcomeId>LZD9i6msXgd</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK funding</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>E2D9B7B5-E8E6-4677-AB73-E527EF1D5A2C</gtr:id><gtr:outcomeId>83FFB5D35400</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>368000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>3258EC0D-84BF-45BD-B9B0-F6E653B9457F</gtr:id><gtr:outcomeId>poQdAtRfWNX</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Comprehensive Biomedical Research Centre, Guy's and St Thomas</gtr:department><gtr:description>Biomedical Research Centre, Programme Grant</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>3E43D33A-03AB-45F4-8239-9EE50BFF6A5B</gtr:id><gtr:outcomeId>BC3AEB9B37E0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2019424</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>WHRS_P41413</gtr:fundingRef><gtr:id>27429730-C5ED-44AB-8671-8B4581D1348A</gtr:id><gtr:outcomeId>dSPo3zaKjUr</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>EEE9A3BE-AB20-4F71-B0C7-E0DFE19D2A19</gtr:id><gtr:outcomeId>PPFDkZErgfF0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Our previous research showed that IgE is produced in the bronchial mucosa of both atopic and non-atopic asthma. The anti-IgE Ab Xolair is used to treat atopic asthma patients but non-atopic asthma patients are excluded from this treatment. We are performing a clinical trial to see if Xolair is of benefit to non-atopic asthma patients.</gtr:description><gtr:id>16CD5DFE-796D-4FDD-AAD9-0D5215711D4A</gtr:id><gtr:impact>Non-atopic asthma patients (one-third of all asthma patients) are resistant to conventional treatments (e.g. steroids) and suffer from very severe symptoms. There is an urgent need to find an effective treatment.</gtr:impact><gtr:outcomeId>kxD6j3iAPbQ</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Immunotherapy of non-atopic asthma with Xolair</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The Ab is active in ADCC of ovarian tumour cells. We are in the late stage of pre-clinical trials and the Ab is under development to produce GMP product for first in man clinical trials.</gtr:description><gtr:id>70EDBB2B-1A6B-41FB-A426-51F5AD8328A1</gtr:id><gtr:impact>The clinical trial is scheduled to begin next summer pending the results of further pre-clinical developments.</gtr:impact><gtr:outcomeId>gy6eiGWv1oo</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>IgE Ab against an ovarian tumour-specific antigen</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Probes to visualise the IgE gene in single cell by confocal microscopy</gtr:description><gtr:id>2B390BE1-5443-48FC-AC4D-BEC536EF023F</gtr:id><gtr:impact>publications</gtr:impact><gtr:outcomeId>iuZzUGJ3Hqx</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>FISH probes</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>results indicate the signalling pathway of soluble CD23 in the stimulation of IgE synthesis</gtr:description><gtr:id>C27A26D0-55A4-40D6-AFD5-02B24A2D1A5A</gtr:id><gtr:impact>one publication and the basis of future research</gtr:impact><gtr:outcomeId>B087110AF35</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>new model of mechanism</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Our experiments provided proof of prinicple that small molecule inhibitors of the IgE-high affinity IgE receptor interaction would be efficacious.</gtr:description><gtr:id>D0448CC5-A54B-445E-A4BF-72C4DC4B1FA1</gtr:id><gtr:impact>UCB, Guy's and St. Thomas' Trust, Asthma UK have funded ongoing research to develop small molecule inhibitors.</gtr:impact><gtr:outcomeId>D8A8077A718</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>small molecule inhibitors of IgE</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>developed transgenic mouse and rat models</gtr:description><gtr:id>BD00004B-4D6E-4D55-B0E5-B08AA80345C3</gtr:id><gtr:impact>several publications</gtr:impact><gtr:outcomeId>B84F6663CA0</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>IgE immunotherapy of cancer</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>IL-4 and anti-CD40 stimulation of IgE synthesis in tonsil B cells</gtr:description><gtr:id>69610D8F-C8E2-4BD6-9C96-44A28219225F</gtr:id><gtr:impact>use of assays</gtr:impact><gtr:outcomeId>7B5A582B099</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>assays for IgE synthesis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Antibodies can be used for structural and functional studies, e.g. determining the crystal structures of allergen-Ab Fa complexes to understand allergenicity or the ability to block the interaction of allergens with IgE</gtr:description><gtr:id>7BFAA066-1948-47AB-B2B4-3BF29C0BAD06</gtr:id><gtr:impact>One publication in Journal of Allergy and Clinical Immunology, others in preparation</gtr:impact><gtr:outcomeId>tWAFZhQ4w64</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>recombinant allergen-specific Abs production</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B8E967AF-9DF9-40E0-9F35-A9E230383CC4</gtr:id><gtr:title>IgE responses in mouse and man and the persistence of IgE memory.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d366311edfeaa1ca0c49c81e1c1a6e0a"><gtr:id>d366311edfeaa1ca0c49c81e1c1a6e0a</gtr:id><gtr:otherNames>Gould HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn><gtr:outcomeId>56cde72a812212.63453983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09EB8F0E-E8E6-4630-8E0D-0825BD2F7702</gtr:id><gtr:title>Intrinsic properties of germinal center-derived B cells promote their enhanced class switching to IgE.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abff5f3c583fc3f81163ddc836927686"><gtr:id>abff5f3c583fc3f81163ddc836927686</gtr:id><gtr:otherNames>Ramadani F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>56cde4b7bd8d85.22594271</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67F08892-04D4-4405-855B-30347B19B399</gtr:id><gtr:title>Soluble CD23 monomers inhibit and oligomers stimulate IGE synthesis in human B cells.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7389df9170532df71986f61b6b72f81"><gtr:id>c7389df9170532df71986f61b6b72f81</gtr:id><gtr:otherNames>McCloskey N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>MzVL2F7CUa5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B58132FE-E1E1-4ADB-A160-AA77188586C9</gtr:id><gtr:title>Comprehensive FISH probe design tool applied to imaging human immunoglobulin class switch recombination.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db4874384846dee1ab627dad2682602b"><gtr:id>db4874384846dee1ab627dad2682602b</gtr:id><gtr:otherNames>Nedbal J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>XT2cYUohmML</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8520005-EE9E-43C1-97F6-CE4551E98FA3</gtr:id><gtr:title>High resolution analysis of the chromatin landscape of the IgE switch region in human B cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7568958c1469c3977509571c8cc9d26c"><gtr:id>7568958c1469c3977509571c8cc9d26c</gtr:id><gtr:otherNames>Dayal S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>Ls4ukt5BBYt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21C6B990-5A6F-466C-82AE-D63E054769C4</gtr:id><gtr:title>Ontogeny of human IgE-expressing B cells and plasma cells.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abff5f3c583fc3f81163ddc836927686"><gtr:id>abff5f3c583fc3f81163ddc836927686</gtr:id><gtr:otherNames>Ramadani F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>58bfecc1a87110.07309185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFCD5F93-22AF-4827-B7D5-D99EB9FABF73</gtr:id><gtr:title>Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FceRI.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1cd44326634381f2c4a83a751b43ea0"><gtr:id>a1cd44326634381f2c4a83a751b43ea0</gtr:id><gtr:otherNames>Dhaliwal B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_15345_25_22802656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD1A9D2D-F2A4-4E55-B4C2-2B4134892552</gtr:id><gtr:title>The who, where, and when of IgE in allergic airway disease.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98c3af7830806528f76d378e70b8c7dd"><gtr:id>98c3af7830806528f76d378e70b8c7dd</gtr:id><gtr:otherNames>Dullaers M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_15345_25_22168998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D8F4300-0730-4FC3-821F-B62B436610ED</gtr:id><gtr:title>Mapping of the CD23 binding site on immunoglobulin E (IgE) and allosteric control of the IgE-Fc epsilonRI interaction.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ab9dd681c7861cbaa73d34677709afe"><gtr:id>4ab9dd681c7861cbaa73d34677709afe</gtr:id><gtr:otherNames>Borthakur S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_15345_25_22815482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23080CF9-8718-43F6-AFB6-60316E043852</gtr:id><gtr:title>Soluble CD23 controls IgE synthesis and homeostasis in human B cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4726c27867b62772e7873f5ec3ae3e94"><gtr:id>4726c27867b62772e7873f5ec3ae3e94</gtr:id><gtr:otherNames>Cooper AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15345_25_22393152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4926F202-E947-43BC-9203-F6CDDB451525</gtr:id><gtr:title>Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e99419069b860ea088ea32ca81cb26b1"><gtr:id>e99419069b860ea088ea32ca81cb26b1</gtr:id><gtr:otherNames>James LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_15345_25_22583928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDE68E0C-76F8-4F74-90B5-FABD5C6FB2B9</gtr:id><gtr:title>Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7e9e87d6eaa9368df0a2aaafdf0cdd5"><gtr:id>b7e9e87d6eaa9368df0a2aaafdf0cdd5</gtr:id><gtr:otherNames>Gevaert P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>QFEhhfbeuGe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4C079D9-FCE6-452E-A9D2-BA6EAECF8842</gtr:id><gtr:title>Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c11f0fc7f828a365a5b00dfb947462a"><gtr:id>1c11f0fc7f828a365a5b00dfb947462a</gtr:id><gtr:otherNames>Karagiannis SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn><gtr:outcomeId>pm_15345_25_22139135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66F21123-EA0F-45E3-9077-FC9B77FCE9B8</gtr:id><gtr:title>Analysis of intergenic transcription and histone modification across the human immunoglobulin heavy-chain locus.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b6c9ebd29f3dcd893759126a2cab4e6"><gtr:id>5b6c9ebd29f3dcd893759126a2cab4e6</gtr:id><gtr:otherNames>Chowdhury M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>AC725587503</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400106</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>